0000790526-25-000008
SEC filingRevenue growth driven by Imaging Center volume/mix and Digital Health expansion, but operating margin compressed by cost pressures and investment.
For the nine months ended September 30, 2025, RadNet reported total revenue of $1.492B, up 10.3% from $1.353B in the prior-year period. Imaging Center segment revenue grew 9.9% to $1.457B, driven by 5.7% same-center revenue growth on 1.6% procedure volume growth and a favorable mix shift toward advanced imaging (MRI up 6.5%, CT up 4.3%, PET/CT up 12.8%). Digital Health revenue surged 38.2% to $64.8M, primarily from the iCAD acquisition completed in mid-2025.
Operating income declined 17.6% to $151.2M, resulting in an operating margin of 10.1% versus 13.6% a year ago. The compression was driven by higher operating expenses: medical supplies expense increased 21.1% ($15.8M) due to higher-cost isotope tracers for PET/CT; lease abandonment charges totaled $8.3M (none in prior year); and stock-based compensation nearly doubled to $38.1M. Interest expense decreased 16.2% to $51.8M, benefiting from the Q4 2024 repricing of the Barclays credit facility, partially offset by $100M incremental term loan borrowings in Q2 2025. Net loss attributable to RadNet common stockholders widened to $18.1M from $2.6M, reflecting the operating income decline and higher non-operating adjustments.
Imaging Center: Same-center revenue growth of 5.7% in the nine months was supported by 4.4% procedure volume growth in the third quarter. Advanced imaging procedures (MRI, CT, PET/CT) outpaced routine imaging, driving higher revenue per procedure. The segment added 8 net new centers YoY, ending at 407 centers. Operating income for the Imaging Center segment grew modestly to $162.7M (up from $185.2M in 9M 2024? Actually the text shows $162.7M vs $185.2M, a decline of 12.2%). Wait: The text says operating income for Imaging Center nine months 2025 is $162,676k vs $185,165k in 2024, a decrease. The MD&A indicates higher costs outpaced revenue growth. Key cost drivers: salaries up 9.5%, medical supplies up 21.1%, lease abandonment charges.
Digital Health: Revenue accelerated in Q3 2025 (+51.6% YoY) due to the iCAD acquisition, bringing external revenue to 59% of total segment revenue. Procedure volumes processed increased from 4.9M to 6.6M, and customer count expanded from 477 to 2,042. However, segment operating loss widened to $23.1M for the nine months, as operating expenses grew 55.9%, driven by higher headcount, R&D (non-capitalized R&D of $13.8M), and stock compensation. Management expects continued net losses in the near term as integration of iCAD and See-Mode progresses.
Management did not provide specific numerical guidance but noted they expect to fund future acquisitions with cash flow from operations and borrowings. The company highlighted ongoing investments in AI and digital health, including the Enhanced Breast Cancer Detection program and cloud-native operating system (DeepHealth OS). Key strategic priorities include expanding the Digital Health customer base, integrating recent acquisitions (iCAD, See-Mode), and optimizing the Imaging Center portfolio, as evidenced by lease abandonment charges from center closures. Cash flow from operations remained healthy at $214.7M, and the company had $804.7M in cash and equivalents at quarter end with ample liquidity under credit facilities ($325M available). The MD&A did not provide specific revenue or earnings guidance.
As of September 30, 2025, RadNet held $804.7M in cash and equivalents, up $64.7M from December 31, 2024. Total debt stood at $1,096.3M (including current portion), an increase of $80.1M driven by a $100M incremental term loan added in June 2025. The company had no outstanding borrowings under its $282M Barclays revolving credit facility and $50M Truist facility, providing $325M in undrawn capacity. Total liabilities were $2,351.3M, equity attributable to RadNet was $1,058.5M, and total equity including noncontrolling interests was $1,313.9M. Deferred revenue was $8.2M.
The notes disclose contingent consideration liabilities related to acquisitions: $8.8M for See-Mode Technologies and $4.5M for Kolb Radiology, recorded in accrued expenses and other non-current liabilities. Operating lease liabilities total $751.3M, with $60.3M current. The company has no material purchase commitments for goods or services beyond normal operations.
During the nine months ended September 30, 2025, RadNet invested $162.2M in property and equipment (10.9% of total revenue) and $66.5M in acquisitions, including iCAD ($110.7M in stock) and See-Mode ($28.7M). Debt activity included $99M of new debt issuance (net) and $20.7M in principal repayments. No share repurchases or dividends were executed. The company's primary capital allocation strategy focuses on organic growth capex and strategic acquisitions in the imaging and digital health segments.
For Q3 2025, the Imaging Center segment generated $508.2M in external revenue (97.2% of total) and segment profit of $74.0M (14.6% margin). Digital Health contributed $14.6M in external revenue (2.8%) but recorded a segment loss of $4.3M, reflecting investment in AI and software initiatives. Intersegment revenue from Digital Health to Imaging Center was $10.2M. Year-over-year, Imaging Center revenue grew 12.3% (driven by volume and acquisitions), while Digital Health revenue surged 66.7% (bolstered by iCAD and See-Mode contributions). Geographic mix is not disclosed in the notes.